STAT Plus: Thousands of sickle cell and hemophilia patients are waiting for gene therapies. Can manufacturers keep up?
ANNIE CAVANAGH/WELLCOME COLLECTION
Gene therapy companies are facing a crucial question: Can they make enough of the viral vectors that ferry repair genes into cells?
No hay comentarios:
Publicar un comentario